Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer

Journal of the National Cancer Institute

Volumn 91, Issue 9, 1999, Pages 763-771

  Swisher, Stephen G ^a   Roth, Jack A ^a   Nemunaitis, John ^b   Lawrence, David D ^a   Kemp, Bonnie L ^a   Carrasco, Cesar H ^a   Connors, Dee G ^c   El Naggar, Adel K ^a   Fossella, Frank ^a   Glisson, Bonnie S ^a   Hong, Waun K ^a   Khuri, Fadlo R ^a   Kurie, Jonathan M ^a   Lee, Jack J ^a   Lee, Jin S ^a   Mack, Michael ^f   Merritt, James A ^c   Nguyen, Dao M ^d   Nesbitt, Jonathan C ^e   Perez Soler, Roman ^a   Pisters, Katherine M W ^a   Putnam Jr , Joe B ^a   Richli, William R ^a   Savin, Michael ^f   Schrump, David S ^d   Shin, Dong M ^a   Shulkin, Allan ^f   Walsh, Garrett L ^a   Wait, Juliette ^f   Weill, David ^f   Waugh, M Kimberly A ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c Introgen Therapeutics Inc   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e C/V Associates   (United States)

^f Box 109 ^*

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; VIRUS VECTOR;

ADENOVIRUS; ADULT; ADVANCED CANCER; AGED; ANOREXIA; APOPTOSIS; ARTICLE; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEMOPTYSIS; HUMAN; HUMAN TISSUE; INJECTION PAIN; INTRATUMORAL DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; PHASE 1 CLINICAL TRIAL; PNEUMOTHORAX; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0033526357     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.9.763     Document Type: Article

References (41)

1. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994; 266:1821-8.
2. Kastan MB, Canman CE, Leonard CJ. p53, cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rev 1995;14:3-15.
3. Mukhopadhyay T, Maxwell SA, Roth JA. p53 suppressor gene. Austin (TX): R. G. Landes Co.; 1995.
4. Spitz FR, Nguyen D, Skibber JM, Meyn RE, Cristiano RJ, Roth JA. Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation. Clin Cancer Res 1996;2:1665-71.
5. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993;362: 847-9.
6. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-67.
7. Fujiwara T, Cai DW, Georges RN, Mukhopadhyay T, Grimm EA, Roth JA. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst 1994;86:1458-62.
8. Zhang WW, Fang X, Mazur W, French BA, Georges RN, Roth JA. Highefficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther 1994;1:5-13.
9. Kock H, Harris MP, Anderson SC, Machemer T, Hancock W, Sutjipto S, et al. Adenovirus-mediated p53 gene transfer suppresses growth of human glioblastoma cells in vitro and in vivo. Int J Cancer 1996;67:808-15.
10. Harris MP, Sutjipto S, Wills KN, Hancock W, Cornell D, Johnson DE, et al. Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein. Cancer Gene Ther 1996;3:121-30.
11. Mujoo K, Maneval DC, Anderson SC, Gutterman JU. Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. Oncogene 1996;12:1617-23.
12. Nielsen LL, Dell J, Maxwell E, Armstrong L, Maneval D, Catino JJ. Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts. Cancer Gene Ther 1997;4:129-38.
13. Wills KN, Maneval DC, Menzel P, Harris MP, Sutjipto S, Vaillancourt MT, et al. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum Gene Ther 1994;5: 1079-88.
14. Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 1996;2:985-91.
15. Stratford-Perricaudet LD, Perricaudet M. Gene therapy: the advent of adenovirus. In: Wolff JA, editor. Gene therapeutics: methods and applications of direct gene transfer. Boston (MA): Birkhauser; 1994. p. 344-62.
16. Blaese M, Blankenstein T, Brenner M, Cohen-Haguenauer O, Gansbacher B, Russell S, et al. Vectors in cancer therapy: how will they deliver. Cancer Gene Ther 1995;2:291-7.
17. Roth JA. Clinical protocol for modification of tumor suppressor gene expression and induction of apoptosis in non-small cell lung cancer (NSCLC) with an adenovirus vector expressing wildtype p53 and cisplatin. Hum Gene Ther 1995;6:252-5.
18. Zhang WW, Fang X, Branch CD, Mazur W, French BA, Roth JA. Generation and identification of recombinant adenovirus by liposome-mediated transfection and PCR analysis. Biotechniques 1993;15:868-72.
19. Nishio M, Koshikawa T, Kuroishi T, Suyama M, Uchida K, Takagi Y, et al. Prognostic significance of abnormal p53 accumulation in primary, resected non-small-cell lung cancers. J Clin Oncol 1996;14:497-502.
20. Chung KY, Mukhopadhyay T, Kim J, Casson A, Ro JY, Goepfert H, et al. Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract. Cancer Res 1993;53:1676-83.
21. Roth JA. Modification of tumor suppressor gene expression and induction of apoptosis in non-small cell lung cancer (NSCLC) with an adenovirus vector expressing wildtype p53 and cisplatin. Hum Gene Ther 1996;7: 1013-30.
22. Zhang WW, Alemany R, Wang J, Koch PE, Ordonez NG, Roth JA. Safety evaluation of Ad5CMV-p53 in vitro and in vivo. Hum Gene Ther 1995;6: 155-64.
23. Ajani JA, Welch SR, Raber MN, Fields WS, Krakoff IH. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 1990;8: 147-59.
24. Fujiwara T, Grimm EA, Mukhopadhyay T, Cai DW, Owen-Schaub LB, Roth JA. A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res 1993;53:4129-33.
25. Wang J, Bucana CD, Roth JA, Zhang WW. Apoptosis induced in human osteosarcoma cells is one of the mechanisms for the cytocidal effect of Ad5CMV-p53. Cancer Gene Ther 1995;2:9-17.
26. Cai DW, Mukhopadhyay T, Liu Y, Fujiwara T, Roth JA. Stable expression of the wild-type p53 gene in human lung cancer cells after retrovirus-mediated gene transfer. Hum Gene Ther 1993;4:617-24.
27. Cai DW, Mukhopadhyay T, Roth JA. Suppression of lung cancer cell growth by ribozyme-mediated modification of p53 pre-mRNA. Cancer Gene Ther 1995;2:199-205.
28. Roth JA, Swisher SG, Merritt JA, Lawrence DD, Kemp BL, Carrasco CH, et al. Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement. Semin Oncol 1998;25(3 Suppl 8):33-7.
29. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin 1997;47:5-27.
30. Clayman GL, el-Naggar AK, Lippman SM, Henderson YC, Frederick M, Merritt JA, et al. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol 1998;16:2221-32.
31. Sterman DH, Treat J, Litzky LA, Amin KM, Coonrod L, Molnar-Kimber K, et al. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 1998;9: 1083-92.
32. Tursz T, Cesne AL, Baldeyrou P, Gautier E, Opolon P, Schatz C, et al. Phase I study of a recombinant adenovirus-mediated gene transfer in lung cancer patients. J Natl Cancer Inst 1996;88:1857-63.
33. Johnson LG, Pickles RJ, Boyles SE, Morris JC, Ye H, Zhou Z, et al. In vitro assessment of variables affecting the efficiency and efficacy of adenovirus-mediated gene transfer to cystic fibrosis airway epithelia. Hum Gene Ther 1996;7:51-9.
34. Li Z, Rakkar A, Katayose Y, Kim M, Shanmugam N, Srivastava S, et al. Efficacy of multiple administrations of a recombinant adenovirus expressing wild-type p53 in an immune-competent mouse tumor model. Gene Ther 1998;5:605-13.
35. Dai Y, Schwarz EM, Gu D, Zhang WW, Sarvetnick N, Verma IM. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci U S A 1995;92:1401-5.
36. Pearson AS, Spitz FR, Swisher SG, Kataoka M, Sarkiss MG, Meyn RE, et al. Upregulation of the proapoptotic mediators bax and bak following adenovirus-mediated p53 gene transfer in lung cancer cells. Clin Cancer Res. In press 1999.
37. Bursch W, Paffe S, Putz B, Barthel G, Schulte-Hermann R. Determination of the length of the histological stages of apoptosis in normal liver and in altered hepatic foci of rats. Carcinogenesis 1990;11:847-53.
38. Ueda M, Ueki K, Kumagai K, Terai Y, Okamoto Y, Ueki M, et al. Apoptosis and tumor angiogenesis in cervical cancer after preoperative chemotherapy. Cancer Res 1998;58:2343-6.
39. Spitz F, Nguyen D, Skibber J, Meyn R, Cristiano R, Roth J. Enhancement of radiation sensitivity of colorectal cancer cells by adenovirus-mediated p53 gene therapy. Surg Forum 1996;47:481-4.
40. Sozzi G, Miozzo M, Donghi R, Pilotti S, Cariani CT, Pastorino U, et al. Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. Cancer Res 1992;52:6079-82.
41. Brambilla E, Gazzeri S, Lantuejoul S, Coll JL, Moro D, Negoescu A, et al. p53 mutant immunophenotype and deregulation of p53 transcription pathway (Bc12, Bax, and Waf1) in precursor bronchial lesions of lung cancer. Clin Cancer Res 1998;4:1609-18.